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ABSTRACT
Introduction: The management of recurrent malignant
pleural effusions (MPE) can be challenging. Various
options are available, with the most efficacious and
widely used being talc pleurodesis. Talc can either be
applied via a chest drain in the form of slurry, or at
medical thoracoscopy using poudrage. Current
evidence regarding which method is most effective is
conflicting and often methodologically flawed. The
TAPPS trial is a suitably powered, multicentre, open-
label, randomised controlled trial designed to compare
the pleurodesis success rate of medical thoracoscopy
and talc poudrage with chest drain insertion and talc
slurry.
Methods and analysis: 330 patients with a
confirmed MPE requiring intervention will be recruited
from UK hospitals. Patients will be randomised (1:1) to
undergo either small bore (<14 Fr) Seldinger chest
drain insertion followed by instillation of sterile talc
(4 g), or to undergo medical thoracoscopy and
simultaneous poudrage (4 g). The allocated procedure
will be performed as an inpatient within 3 days of
randomisation taking place. Following discharge,
patients will be followed up at regular intervals for
6 months. The primary outcome measure is
pleurodesis failure rates at 3 months. Pleurodesis
failure is defined as the need for further pleural
intervention for fluid management on the side of the
trial intervention.
Ethics and dissemination: The trial has received
ethical approval from the National Research Ethics
Service Committee North West—Preston (12/NW/0467).
There is a trial steering committee which includes
independent members and a patient and public
representative. The trial results will be published in a
peer-reviewed journal and presented at international
conferences, as well as being disseminated via local and
national charities and patient groups. All participants
who wish to know the study results will also be
contacted directly on their publication.
Trial registration number: ISRCTN47845793.
INTRODUCTION
Pleural effusions are a common complication
of many cancers, with symptoms often requir-
ing intervention. Data from 10 years ago
suggest that there are up to 175 000 new
cases of malignant pleural effusion (MPE) in
the USA per year and around 40 000 cases
per year in the UK,1 although these ﬁgures
may now be conservative as the global
burden of malignancy continues to rise each
year, and with it the incidence of MPE.
Pleurodesis is the adherence of the visceral
and parietal pleura, which causes an obliter-
ation of the pleural space. Removing the
pleural space reduces the possibility of
pleural ﬂuid build-up, which means that
induction of pleurodesis is considered the
mainstay of treatment for recurrent MPE.
Many substances have been shown to induce
chemical pleurodesis, although by far the
most commonly used one in Europe and
North America is talc, which has been shown
to be superior to alternatives such as tetracyc-
line or bleomycin.2 Overall, pleurodesis
success rates with talc are typically high,
Strengths and limitations of this study
▪ Suitably powered multicentre, randomised con-
trolled trial of talc pleurodesis interventions in the
general malignant pleural effusion population.
▪ First study to specifically investigate poudrage
using medical thoracoscopy.
▪ Robust 6-month patient follow-up.
▪ Clinically relevant and applicable definition of
pleurodesis success.
▪ Pleurodesis performed as part of diagnostic
thoracoscopy not included.
▪ No comparison with indwelling pleural catheters.
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ranging from 81% to 100%,3 although this efﬁcacy may
vary considerably in real-world practice due to differ-
ences between clinicians and individual centres. The
traditional method to instil talc, the control arm in this
study, requires a patient to be admitted to hospital for
chest tube insertion and ﬂuid drainage. Talc is adminis-
tered as slurry and is made up with a physiologically
inert ﬂuid such as 0.9% saline. The chest tube is
removed once subsequent drainage volumes become
low, potentially indicating successful pleurodesis.
An alternative to this approach is the application of
sterile talc powder under direct vision at thoracoscopy
(insufﬂation or poudrage). However, despite an increas-
ing number of hospitals having access to medical thora-
coscopy, it is still much less ubiquitous than Seldinger
chest drain insertion, with the requirement for specialist
training and the increased costs of the procedure being
major limitations, along with the more complex nature
of the procedure. The efﬁcacy of talc poudrage at
1 month for pleurodesis has been documented in a
number of studies. Published success rates tend to lie
around 85%, although there is signiﬁcant heterogeneity
between study groups limiting reliability. A number of
studies regarding talc slurry and talc poudrage were
compared as part of the 2004 Cochrane review which,
along with suggesting talc was the most efﬁcacious scler-
osant, found talc poudrage at thoracoscopy to have an
improved relative risk of non-recurrence (1.19) over talc
slurry.2 A subsequent large randomised trial by Dresler,
published in 2005, suggested there was only a trend
towards superiority of poudrage (p=0.1), with no signiﬁ-
cant overall difference between the two methods. Post
hoc subgroup analysis demonstrated a rise in pleurodesis
success once patients with trapped lung were excluded,
as well as a signiﬁcant difference between poudrage
(82%) and slurry (71%; p=0.045).4
The role of talc poudrage for the induction of pleur-
odesis and the prevention of ﬂuid recurrence in MPE
remains unclear. Chest drain insertion with talc slurry is
universally available, less expensive and relatively easy to
perform, but may have a signiﬁcantly poorer success rate
and may result in longer hospital stays. The TAPPS trial
aims to deﬁnitively resolve the question of whether talc
poudrage is a superior method for the induction of
pleurodesis in MPE, allowing clinicians to make the
most appropriate and best informed decisions and
recommendations to patients.
METHODS AND ANALYSIS
This study, evaluating the efﬁcacy of thoracoscopy and
talc poudrage versus pleurodesis using talc slurry
(TAPPS trial), is a multicentre, open-label, randomised
controlled trial. The trial is sponsored by the North
Bristol NHS Trust (NBT) and coordinated jointly by the
Academic Respiratory Unit at the University of Bristol
and the Oxford Respiratory Trials Unit (ORTU) at the
University of Oxford. Data management is undertaken
by the ORTU. The trial is registered on the
International Standardised Randomised Controlled Trial
Registry (ISRCTN47845793) and funded by the National
Institute for Health Research (NIHR) Health Technology
Assessment programme. The study is included in the
NIHR Clinical Research Network portfolio (ID: 12537).
The trial will be conducted in accordance with the
Declaration of Helsinki and good clinical practice (GCP).
The primary research question is: For patients with a
conﬁrmed MPE and good performance status, does
thoracoscopy and talc poudrage increase the proportion
of patients with successful pleurodesis at 3 months post-
procedure, when compared with standard therapy with
chest drain insertion and talc slurry instillation?
The secondary research questions are:
1. Does talc poudrage reduce the time to pleurodesis
failure at 3-month and 6-month postprocedure when
compared with talc slurry?
2. Does talc poudrage at thoracoscopy improve chest
X-ray (CXR) appearances after initial drain removal,
and at 1-month, 3-month and 6-month postrandomi-
sation when compared with talc slurry?
3. Does talc poudrage cause less breathlessness and
thoracic pain for the ﬁrst 7 days postrandomisation
when compared with talc slurry?
4. Does talc poudrage improve health-related quality of
life over the 6 months of postrandomisation when
compared with talc slurry?
5. Is talc poudrage cost-effective over 6 months when
compared with talc slurry instillation?
6. Does talc poudrage reduce healthcare utilisation
during the 6-month postrandomisation when com-
pared with talc slurry instillation?
Setting
Three hundred and thirty patients requiring a pleurod-
esis intervention for a conﬁrmed MPE will be recruited
from UK hospitals (see online supplementary appendix
1 for details of recruiting centres). Patients will be ran-
domised to undergo either chest drain insertion followed
by 4 g talc slurry instillation, or to undergo medical thora-
coscopy with 4 g talc poudrage. The study ﬂow diagram is
shown in ﬁgure 1.
Subject screening and selection
Patients with MPE will be identiﬁed following early dis-
cussion at each centre’s cancer multidisciplinary team
meetings (MDT), at routine outpatient appointments
and during inpatient reviews. Eligible patients will be
invited to participate on a consecutive basis, and will be
provided with a patient information leaﬂet at the earliest
opportunity (see online supplementary appendix 2).
Patients can be enrolled only once into the TAPPS trial.
Inclusion criteria
1. Clinically conﬁdent diagnosis of MPE requiring
pleurodesis, deﬁned as:
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A. Pleural effusion with histocytologically proven
pleural malignancy; or
B. Pleural effusion in the context of histocytologically
proven malignancy elsewhere, without a clear
alternative cause for ﬂuid; or
C. Pleural effusion with typical features of malignancy
with pleural involvement on cross-sectional imaging
without a clear alternative cause for ﬂuid.
2. Fit enough to undergo local anaesthetic thoracoscopy.
3. Expected survival >3 months.
4. Written informed consent to trial participation.
Exclusion criteria
1. Patients in whom thoracoscopy is the only reasonable
approach to making a diagnosis, and in whom such a
diagnosis would signiﬁcantly inﬂuence further
management;
2. Age <18 years;
Figure 1 Trial flow chart (BTS, British Thoracic Society; CI, chief investigator; CXR, chest X-ray; QoL, quality of life;
VAS, visual assessment scale; PA, pleural apposition; SOB, shortness of breath).
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3. Females who are pregnant or lactating;
4. Evidence of extensive lung entrapment on CXR or a
CT scan, or signiﬁcant ﬂuid loculation on an ultra-
sound scan, to a level which would normally be a
contraindication to attempted talc pleurodesis;
5. Insufﬁcient volume or position of pleural ﬂuid on
lateral decubitus thoracic ultrasound to safely
perform local anaesthetic thoracoscopy without
further intervention being necessary;
6. Previously documented adverse reaction to talc;
7. Clear contraindication to thoracoscopy or chest tube
insertion.
Informed consent
A doctor will conﬁrm patient eligibility prior to consent
being taken. Participation in the trial will be discussed
with the patient by a medical or nursing member of
the local trial team. Patients will be given sufﬁcient
time (in their own opinion) to fully consider trial entry,
as well as to ask questions of investigators. The consent
form (see online supplementary appendix 3) will be
countersigned by either a medical or nursing member
of the trial team.
Randomisation
Following informed consent, patients will be randomly
assigned in a 1:1 ratio using minimisation with a random
element to undergo either chest drain insertion with
talc slurry pleurodesis or thoracoscopy with talc poud-
rage. The day of randomisation is deﬁned as day
0. Although the allocated trial procedure may be per-
formed within 3 days of randomisation, every effort
should be made to perform the procedure immediately
afterwards.
Treatment allocation will be performed over the tele-
phone by the ORTU. The randomisation sequence will
be generated using a validated, online randomisation
service (Sealed Envelope, London, UK; http://www.
sealedenvelope.com).
The minimisation factors are:
▸ Type of underlying malignant disease (mesothelioma,
lung cancer, breast cancer, other);
▸ WHO/Eastern Cooperative Oncology Group (ECOG)
performance status (0 or 1; 2 or 3).
Patients and clinicians will not be blinded to treatment
allocation.
Standard care
All patients should have been discussed in their local or
regional tumour-speciﬁc MDT. For all issues other than
those pertaining to the drainage and management of
the MPE, treatment discretion lies with the primary
clinician.
Normal clinical review during the trial period will take
place in the usual outpatient or inpatient setting, and
will typically be carried out by oncologists or respiratory
physicians. The frequency of clinical review will depend
on patient choice, severity of symptoms and clinical
discretion. In general, patients who are managed with
chemotherapy for underlying malignancy are typically
reviewed every 2–3 months.
Patients can withdraw from the trial at any time
without their clinical care being affected.
Co-enrolment in other clinical trials will be discussed
on an individual patient basis, but patients should not
be co-enrolled into any trial which speciﬁcally aims to
directly inﬂuence pleural ﬂuid production or drainage.
Interventions
The full trial speciﬁc procedures (TSP) for the two treat-
ment arms can be found in online supplementary
appendices 4 and 6.
Control (talc slurry) arm
Patients will have a small-bore (<14 Fr) chest drain inserted
under aseptic conditions using the Seldinger technique,
with appropriate local anaesthesia and premedication as
necessary. A suitable site for drain placement will be identi-
ﬁed using contemporaneous ultrasound. Drains will only
be inserted by persons with adequate training and experi-
ence. Trial pleural ﬂuid samples (see section below)
should also be taken as necessary.
A CXR should be performed between 18 and 24 h
after drain insertion. If there is no evidence of trapped
lung or signiﬁcant ﬂuid, as determined by the patient’s
primary physician, then the patient should have 4 g talc
slurry instilled through the chest drain, following the
appropriate TSP. Patients who continue to have evidence
of signiﬁcant pleural opaciﬁcation may need to undergo
further imaging to conﬁrm the cause. If the signiﬁcant
component of the opaciﬁcation is felt to be due to
pleural thickening rather than ﬂuid, then slurry instilla-
tion should proceed according to the TSP.
Patients who have evidence of trapped lung, or who
have signiﬁcant opaciﬁcation due to ﬂuid on CXR, may
have thoracic suction applied if it is felt appropriate.
Patients should undergo slurry instillation once the
primary physician is satisﬁed that at least 50% of the visible
pleura are apposed. If, by 48 h post drain insertion, there
is inadequate pleural apposition on CXR, or the primary
physician feels that talc slurry instillation would be inappro-
priate for another reason, then further management deci-
sions lie with the primary physician. Such patients should
continue to receive follow-up in the standard manner and
should have all treatment decisions clearly documented. A
ﬂow chart for patient management in the control arm is
provided (see online supplementary appendix 5).
Following slurry instillation, thoracic suction should be
applied if available and tolerated. Once documented
drainage falls below 250 mL per 24 h (in the presence
of a patent drain), the drain should be removed, unless
the primary physician feels there is reason for the drain
to remain in place for longer. Following drain removal, a
further CXR should be performed and an appointment
given for the ﬁrst trial follow-up visit at 1-month
postrandomisation.
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Intervention (talc poudrage) arm
All participants who undergo thoracoscopy will have their
procedure performed by persons with adequate training
and experience. Patients will be given adequate sedation
(if required) and local anaesthetic for the procedure.
Biopsy samples will be taken as needed. Trial pleural ﬂuid
samples (see section below) should also be taken as
necessary. At the end of the procedure, 4 g of sterile talc
should be sprayed over the pleural surfaces. A 16–24 Fr
chest drain should be inserted at the end of the proced-
ure and connected to an underwater seal. Patients should
be attached to thoracic suction, if available and tolerated.
The future care decisions of any patient whose proced-
ure is abandoned or curtailed before poudrage is per-
formed (at the discretion of the operator) remain with
the primary physician. Such patients will remain under
trial follow-up and should have all care decisions and
associated delays clearly documented in their notes.
A CXR should be performed between 18 and 24 h
after drain insertion to assess lung re-expansion. If there
is evidence of incomplete re-expansion, then drain
patency should be checked. The management of
patients with incomplete lung expansion is at the discre-
tion of the primary physician, and may include the con-
tinued use of thoracic suction.
All patients’ drains should remain in place for a
minimum of 24 h. When a patient has drained 250 mL
or less in the previous 24 h, then the drain should be
removed, unless the primary physician feels that it needs
to remain in place for longer. A ﬂow chart for patient
management in the intervention arm is provided (see
online supplementary appendix 7). Following drain
removal, a further CXR should be performed and an
appointment given for the ﬁrst trial follow-up visit at
1-month postrandomisation.
Data collection and management
Visual assessment scale (VAS) scoring
All patients will document a VAS score for thoracic pain
and breathlessness during their baseline assessment. This
score should then be performed again on the ﬁrst day
postrandomisation, and then daily for 7 days. Following
this, scores should be completed on a weekly basis.
Patient diaries
Patients will be provided with preprinted diaries. They
are to record all personal contact with medical profes-
sionals (excluding trial visits) in a basic standardised
manner. These data will be reviewed at follow-up
appointments and will subsequently be used to deter-
mine the health utilisation of each participant during
the follow-up period.
Biological samples and storage
At all trial sites, those who consent to trial sample ana-
lysis should have 2 EDTA tubes, 1 serum gel tube and 1
lithium heparin tube of blood taken (‘trial blood
samples’). Sites other than Oxford and North Bristol
should send these samples as soon as possible, unpro-
cessed, to the Respiratory Research Unit at Southmead
Hospital. Patients at North Bristol and Oxford should
also have 2 EDTA, 1 serum gel and 1 lithium heparin
tube ﬁlled with pleural ﬂuid during either thoracoscopy
or initial drain insertion (‘trial pleural ﬂuid samples’).
At these sites, trial blood and pleural ﬂuid samples
should be centrifuged, labelled and stored locally ini-
tially as per the appropriate TSP. All processed samples
will eventually be transferred to the Respiratory
Research Unit at North Bristol. Genetic compositional
analysis may also be undertaken on participants’ samples
if speciﬁc consent for this has been obtained.
Additionally, on the second day post talc administra-
tion (or on discharge if sooner), patients should have
blood samples taken and analysed locally for C reactive
protein, full blood count, and urea and electrolytes, with
the results entered onto the discharge case report form.
Trial follow-up appointments
Trial follow-up appointments will take place at 1-month,
3-month and 6 month postrandomisation, with tele-
phone follow-ups being performed if necessary. A CXR
will be performed and patients will undergo a standar-
dised assessment, including a review of their healthcare
resource use diary; EQ-5D and SF-36 quality of life ques-
tionnaires; and a focused medical history.
Further pleural intervention
All patients who are felt to have increasing breathless-
ness should undergo a CXR. Any CXR which shows a
degree of pleural opaciﬁcation ipsilateral to the pleurod-
esis attempt should lead to further imaging to conﬁrm
the presence of ﬂuid. If ﬂuid is conﬁrmed, and the CXR
shows pleural opaciﬁcation to be one-third or greater
than the volume of the hemithorax (by visual estima-
tion), the primary physician should undertake any
further investigations or interventions as deemed appro-
priate. In patients who have less than one-third of the
hemithorax occupied by pleural ﬂuid, the primary phys-
ician should discuss with another local physician who is
blinded to the treatment arm whether pleural interven-
tion is required.
Data management
Clinical Record Forms (CRF) will be completed by the
trial team at recruiting centres and sent to the ORTU.
Data will then be entered onto the trial database
(OpenClinica clinical trials software). Missing data and
data queries will be highlighted to the trial teams on a
monthly basis. The CRFs will only identify patients using
their personal trial identiﬁcation number (no identiﬁ-
able patient information).
Primary outcome
The primary outcome is the number of patients who
experience pleurodesis failure up to 3 months (90 days)
postrandomisation.
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A patient is deﬁned as experiencing pleurodesis
failure if they undergo any of the following procedures
on the side ipsilateral to their trial intervention:
▸ Therapeutic pleural aspiration of ≥100 mL; or
▸ Insertion of an intercostal drain for ﬂuid drainage; or
▸ Insertion of an indwelling pleural catheter; or
▸ Medical or surgical thoracoscopy.
A patient is also deemed to have failed pleurodesis if
their primary physician decides that they require one
of the above pleural interventions, but the intervention
is not performed. The primary physician is not blind
to the treatment arm; however, all decisions to inter-
vene or not in effusions which occupy less than or
equal to one-third of the hemithorax will be discussed
with a second clinician who is blind to treatment
allocation.
Secondary outcomes
The trial’s secondary outcomes are:
1. The number of patients with pleurodesis failure up
to 30 days postrandomisation.
2. The number of patients with pleurodesis failure up
to 180 days postrandomisation.
3. Requirement for further pleural procedures up to
180 days postrandomisation, based on an independ-
ent assessment performed by two adjudicators who
are blind to the treatment outcome and clinical
course.
4. Percentage pleural opaciﬁcation (on CXR) at
1-month, 3-month and 6-month postrandomisation
follow-up visits, and after initial drain removal.
5. Self-reported health-related quality of life at 1-month,
3-month and 6-month follow-up postrandomisation
visits, measured using SF-36 and EQ-5D questionnaires.
6. Self-reported thoracic pain and breathlessness (post-
randomisation) at 7, 30, 90 and 180 days, measured
using VAS scores.
7. All-cause mortality up to 180 days postrandomisation.
8. Time to pleurodesis failure, censored at 180 days
postrandomisation.
9. Number of nights spent in the hospital up to 90 days
postrandomisation, including length of initial hos-
pital stay.
Sample size calculation
Previous literature and our own audit data suggest that
patients with a WHO performance status score of 2 or
better have approximate pleurodesis failure rates of
≤10% with thoracoscopy, and ≥30% with a ‘best standard
of care’ standard chest tube and talc slurry pleurodesis.5
In order to detect a ≥15% difference in pleurodesis
failure at 3 months (10% thoracoscopy and poudrage vs
25% chest drain and talc slurry) with 90% power, a 5%
signiﬁcance level and 10% loss to follow-up, the study
requires 325 patients. For the present analysis, numbers
have been rounded up to include 330 patients (165
patients in each treatment arm).
Statistical analysis plan
The full statistical analysis plan is published elsewhere.
The primary analysis for each outcome will be by
intention to treat. All tests will be two-sided, and will be
considered statistically signiﬁcant at the 5% level. For
each analysis, the following summaries will be provided:
▸ The number of patients in each treatment group who
are included in the analysis.
▸ The mean (SD) or median (IQR) in each treatment
group for continuous outcomes, or the number (%)
of patients experiencing an event for binary or
time-to-event outcomes (time-to-event outcomes will
also present the median time to event in each treat-
ment arm if applicable).
▸ The treatment effect (difference in means for con-
tinuous outcomes, OR for binary outcomes, HR for
time-to-event outcomes, rate ratio for count out-
comes) with its 95% CI and a p value.
All analyses will adjust for minimisation variables (type
of underlying malignant disease (mesothelioma, lung
cancer, breast cancer, other) and WHO performance
status (0–1 or 2–3)).6–9 The minimisation variables will
be included as covariates in the regression model for
each outcome.
CONSORT data will be presented, including: the
number of patients screened for the study; the numbers
randomised; the numbers receiving the interventions;
the numbers lost to follow-up and excluded (with
reasons) and the number of patients included in the
primary analysis.
Subgroup analyses will be performed for the primary
outcome, and the following secondary outcomes: pleur-
odesis failure at 30 and 180 days; requirement for
further pleural procedures; and percentage CXR opaciﬁ-
cation. Results from subgroup analyses will be viewed as
hypothesis generating, and will not be used to make
deﬁnitive statements about treatment efﬁcacy in a spe-
ciﬁc subgroup of patients. The following subgroup ana-
lyses will be performed:
▸ Patients receiving anticancer therapy at baseline
versus those not receiving;
▸ Previous radiotherapy to chest versus no previous
radiotherapy to chest;
▸ WHO performance status 0–1 versus 2–3;
▸ Patients on non-steroidal anti-inﬂammatory drugs
(NSAIDS) at baseline versus those not on NSAIDS at
baseline;
▸ Patients on steroids at baseline versus those not on
steroids at baseline;
▸ Previous attempt at pleurodesis within the past
month versus no attempt in the past month;
▸ Patients with primary malignancy of breast cancer
versus mesothelioma versus lung cancer versus other.
Changes to the protocol after trial commencement
The trial details documented here are consistent
with the TAPPS Trial protocol V.6 (date: 06/10/2014).
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A summary of the trial amendments can be found in
online supplementary appendix 8.
In September 2013, the ‘window’ in which individuals
could undergo their allocated trial procedure was
extended from 24 to 72 h postrandomisation.
End of trial
The trial will end once 330 patients have been recruited
and all patients have died or completed 6 months of
trial follow-up (whichever is sooner).
ETHICS AND DISSEMINATION
Monitoring
An independent data monitoring committee (IDMC)
will be convened at regular intervals, consisting of
members who are independent of the trial investigators.
The role of the IDMC is to review study safety data and
provide advice to the trial steering committee (TSC),
speciﬁcally as to whether recruitment can continue. No
interim analysis is planned.
Safety reporting
Data will be collected at each patient’s trial visit regard-
ing any serious adverse events (SAE; as deﬁned by
GCP). All SAEs causally related to trial interventions
will be reported to the sponsor and to the relevant
oversight bodies, and will be followed until they resolve
or stabilise.
Trial monitoring and oversight
The TSC will be responsible for overseeing the progress
of the trial and will meet at approximate six monthly
intervals. The TSC will comprise of independent chair-
person, independent members, statistician, patient and
public representative and members of the trial team.
Dissemination
The trial will be publicised at regional and national con-
ferences. The ﬁnal results will be presented at scientiﬁc
meetings and published in a peer-reviewed journal
(authorship will be according to the journal’s guide-
lines). In addition, a lay summary of the study results
will be circulated to potentially interested parties.
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